Shots:

• The results from the OLE of the P-III (MPOWERED) non-inferiority trial evaluate Mycapssa vs iSRLs in 146 patients with acromegaly who have responded to & tolerated treatment with inj. octreotide or lanreotide
• In the P-III study, patients switched from iSRLs to Mycapssa showed an improvement in acromegaly symptom control, 47% with good symptomatic control at end of RCT that increased to 79% at end of the OLE & the median compliance rate of 99%, IGF-1 levels were maintained
• Additionally, patients maintained biochemical response with 94%, 90% & 93% @ 1, 2 & 3yr. of the OLE. The safety profile was consistent with the core study & no new safety signals were observed with long-term exposure

Ref: Globe Newswire | Image: Globe Newswire